ArticleFrontiers in medicine2025
Prevalence of and factors associated with sarcopenia in patients on hemodialysis in Brazil: findings from the multicenter SARC-HD study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- The Link Between Dietary Indices, Sarcopenia, and Clinical Parameters in Diabetic and Non-Diabetic Hemodialysis Patients.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The understanding of sarcopenia in patients on hemodialysis from middle-income countries remains underexplored. We investigated the prevalence of and factors associated with sarcopenia in patients undergoing hemodialysis in Brazil. Methods: This was a cross-sectional analysis using baseline data from the Results: A total of 983 patients (median age 59 years; 48% ≥ 60 years; 40% female) from 19 dialysis centers were analyzed. The prevalences of probable, confirmed, and severe sarcopenia were 12, 9, and 5%, respectively. Sarcopenia prevalence increased with age, ranging from 7 to 45% in the male individuals and from 4 to 21% in the female individuals. In the fully adjusted model, older age [≥60 years; adjusted odds ratio (aOR): 3.30, 95% confidence interval (CI): 2.09-5.21], male sex (aOR: 1.77, 95% CI: 1.13-2.77), white ethnicity (aOR: 1.88, 95% CI: 1.23-2.87), and diabetes as the etiology/comorbidity of chronic kidney disease (CKD) (aOR: 1.83, 95% CI: 1.20-2.91) were independently associated with higher odds of sarcopenia. Nevertheless, overweight (aOR: 0.38, 95% CI: 0.24-0.60) and obesity (aOR: 0.11, 95% CI: 0.05-0.26) were associated with lower odds. After sensitivity analyses based on dialysis prescription, only older age, white ethnicity, overweight, and obesity remained independently associated with sarcopenia. Conclusion: One in four patients on hemodialysis had some stage of sarcopenia. Independent risk factors associated with sarcopenia were older age and white ethnicity, whereas overweight and obesity were protective factors. These findings may help identify hemodialysis patients at increased risk of sarcopenia, thereby promoting early screening, diagnosis, and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.